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Abstract
Introduction Sox9 and p300 cooperate to induce expression of
cartilage-specific matrix proteins, including type II collagen,
aggrecan and link protein. Tumour necrosis factor (TNF)-α,
found in arthritic joints, activates nuclear factor-κB (NF-κB),
whereas retinoic acid receptors (RARs) are activated by retinoid
agonists, including all-trans retinoic acid (atRA). Like Sox9, the
activity of NF-κB and RARs depends upon their association with
p300. Separately, both TNF-α and atRA suppress cartilage
matrix gene expression. We investigated how TNF-α and atRA
alter the expression of cartilage matrix genes.
Methods Primary cultures of rat chondrocytes were treated with
TNF-α and/or atRA for 24 hours. Levels of transcripts encoding
cartilage matrix proteins were determined by Northern blot
analyses and quantitative real-time PCR. Nuclear protein levels,
DNA binding and functional activity of transcription factors were
assessed by immunoblotting, electrophoretic mobility shift
assays and reporter assays, respectively.
Results Together, TNF-α and atRA diminished transcript levels
of cartilage matrix proteins and Sox9 activity more than each
factor alone. However, neither agent altered nuclear levels of
Sox9, and TNF-α did not affect protein binding to the Col2a1
48-base-pair minimal enhancer sequence. The effect of TNF-α,
but not that of atRA, on Sox9 activity was dependent on NF-κB
activation. Furthermore, atRA reduced NF-κB activity and DNA
binding. To address the role of p300, we over-expressed
constitutively active mitogen-activated protein kinase kinase
kinase (caMEKK)1 to increase p300 acetylase activity.
caMEKK1 enhanced basal NF-κB activity and atRA-induced
RAR activity. Over-expression of caMEKK1 also enhanced basal
Sox9 activity and suppressed the inhibitory effects of TNF-α and
atRA on Sox9 function. In addition, over-expression of p300
restored Sox9 activity suppressed by TNF-α and atRA to normal
levels.
Conclusion NF-κB and RARs converge to reduce Sox9 activity
and cartilage matrix gene expression, probably by limiting the
availability of p300. This process may be critical for the loss of
cartilage matrix synthesis in inflammatory joint diseases.
Therefore, agents that increase p300 levels or activity in
chondrocytes may be useful therapeutically.
Introduction
Members of the Sry-type high mobility group box (Sox) tran-
scription factor family are regulators of tissue-specific gene
expression (for review, see Wegner [1]). A subset of Sox pro-
teins is responsible for controlling cartilage development and
chondrocyte function by regulating the expression of specific
matrix genes. L-Sox5, Sox6 and Sox9 are necessary regula-
tors for induction and maintenance of cartilage-specific colla-
gen expression by chondrocytes [2]. L-Sox5 and Sox6
heterodimerize via inherent leucine zippers and bind DNA, but
they lack transactivation domains necessary to control tran-
scription. In contrast, Sox9 contains a carboxyl-terminal trans-
activation domain and probably serves to regulate gene
transcription directly. Consequently, L-Sox5 and Sox6 syner-
gize with Sox9 to induce transcription of the type II collagen
gene by binding to the 48-base-pair (bp) minimal enhancer
region [2-4]. Sox9 also coordinates expression of two other
atRA = all-trans retinoic acid; bp = base pair; caMEKK = constitutively active mitogen-activated protein kinase kinase kinase; EMSA = electrophoretic 
mobility shift assay; IκB = inhibitor of nuclear factor-κB; NF-κB = nuclear factor-κB; PCR = polymerase chain reaction; qPCR = quantitative real-time 
polymerase chain reaction; RAR = retinoic acid receptor; RARE = retinoic acid response element; Sox = Sry-type high mobility group box; TNF = 
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cartilage extracellular matrix molecules, aggrecan and link pro-
tein, through activity at regulatory regions of each gene [5,6].
Homeostatic maintenance of mature cartilage is characterized
by continual production and degradation of extracellular
matrix, processes that are coordinated in chondrocytes via
factors such as the Sox proteins. In contrast, cartilage degen-
eration in joint diseases such as rheumatoid arthritis and oste-
oarthritis results from a shift in this balance toward catabolism.
One factor found in the synovial fluid of rheumatoid and oste-
oarthritic patients is the inflammatory cytokine tumour necrosis
factor (TNF)-α [7-9]. In addition to upregulating the expression
of catabolic factors such as matrix metalloproteinases and
aggrecanases [10,11], TNF-α downregulates expression of
transcripts for type II collagen, aggrecan and link protein by
chondrocytes [12-14]. Signalling events that mediate these
changes in gene expression include activation of nuclear fac-
tor-κB (NF-κB), extracellular signal-regulated kinases 1/2 and
p38 mitogen-activated protein kinase pathways, and
decreases in Sox9 protein expression [13-15].
Inhibitor of NF-κB (IκB) mask the nuclear localization signal on
NF-κB. When cells are stimulated by TNF-α, IκB is phosphor-
ylated by activated IκB kinase. Phosphorylated IκB is ubiquiti-
nated and degraded by the 26S proteasome, permitting NF-
κB isoforms to homodimerize or heterodimerize, enter the
nucleus and alter gene transcription (for review, see Karin and
Ben-Neriah [16]). Preventing the activation of NF-κB allows
Sox9 to retain its full activity at the type II collagen enhancer in
the presence of TNF-α [13], suggesting a relationship
between these transcription factors.
Some transcription factors can be directly regulated by bind-
ing of membrane-permeable agonists. An example of such an
agonist is all-trans retinoic acid (atRA), a metabolite of vitamin
A, that is bound preferentially by the α, β and γ retinoic acid
receptors (RARs) [17]. RARs act as homodimers or het-
erodimers with members of the retinoid X receptor family to
transactivate genes.
Regulation of retinoid signalling is critical for the development
and maintenance of cartilage. In chondroprogenitor cells, acti-
vation of retinoid receptors, particularly RARα, decreases
Sox9 activity at the type II collagen enhancer and reduces the
content of glycosaminoglycans in the extracellular matrix.
Moreover, treatment of equine articular cartilage explants with
atRA results in loss of glycosaminoglycans as a consequence
of reduced proteoglycan synthesis [18]. Furthermore, mice
fed a diet high in retinyl acetate, a synthetic derivative of vita-
min A, exhibit cartilage atrophy and other osteoarthritic char-
acteristics [19]. In addition, increasing retinoid levels in
humans accelerates hypertrophy of chondrocytes and ossifi-
cation (hyperostosis), which contributes to the progression of
degenerative joint diseases [20]. Thus, retinoids, including
atRA, appear to have negative effects on matrix synthesis and
homeostasis in cartilage.
Interestingly, adult mice fed diets deficient in vitamin A exhibit
generalized increases in basal NF-κB activity [21]. Upon
administration of retinoic acid, NF-κB activity is reduced,
which suggests an effect of RARs on function rather than
expression of NF-κB. Recombinant NF-κB p65 and members
of both the RAR and retinoid X receptor families of retinoic
acid receptors associate with each other in vitro [22]. Further-
more, addition of an atRA analogue to macrophage cell
extracts decreases TNF-α-induced binding of NF-κB to DNA
[22]. Consistent with these results, administration of atRA
reduces joint destruction in collagen-induced inflammatory
arthritis [23].
Co-factors associated with regulatory transcription factors
play vital roles in the transactivation of genes. Sox9, NF-κB
and RARs share the common co-factor p300, an acetylase
that is required for full activity of these transcription factors
[24-26]. In the present study, we investigated the mechanism
by which such transcription factors integrate to regulate gene
expression. We determined the effect of co-activation of NF-
κB and RARs on Sox9 function and cartilage matrix gene
expression. We found that atRA and TNF-α signalling con-
verge in the nucleus to promote greater reductions in Sox9
activity and matrix gene expression than signalling from each
alone. These reductions in Sox9 activity are consistent with
limitation in the availability of p300 for Sox9 when NF-κB and
RARs are also activated. Thus, agents that promote p300
activity or availability may be useful therapeutically to maintain
cartilage matrix production in inflammatory joint disease.
Materials and methods
Cell culture
Primary chondrocytes were isolated (8 to 12 × 105 cells/rat)
from the femoral condyles of 1-day-old Sprague Dawley rats
(Charles River, St. Hyacinthe, Quebec, Canada), as described
previously [13]. The Animal Use Subcommittee of the Univer-
sity of Western Ontario Council on Animal Care approved the
use of rats in these studies. Chondrocytes were plated on tis-
sue culture plastic (Falcon, Franklin Lakes, NJ, USA) at a den-
sity of 3.0 to 4.25 × 104 cells/cm2 and grown in RPMI-1640
media supplemented with 5% foetal bovine serum, 100 U/ml
penicillin, 100 μg/ml streptomycin and 10 mmol/l HEPES (Inv-
itrogen Life Technologies Inc., Burlington, Ontario, Canada).
The medium was changed every 3 days until cultures reached
confluence, typically after 6 to 8 days.
RNA isolation, Northern blot hybridization and real-time 
PCR
Total RNA was isolated using Trizol (Invitrogen Life Technolo-
gies Inc.) and quantified spectrophotometrically. Northern blot
hybridizations were performed as described previously [13]
using probes corresponding to the C-propeptide of mouseAvailable online http://arthritis-research.com/content/10/1/R3
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type II collagen (pKN225) [3], rat aggrecan core protein
(p1353) [27] and mouse 18S rRNA (Ambion, Austin, TX,
USA), radiolabelled with [α32P]-dCTP (3000 Ci/mmol; NEN,
Boston, MA, USA) using a random-primed oligonucleotide
method (Prime-a-gene labeling kit; Promega, Madison, WI,
USA). For quantitative real-time PCR (qPCR) analysis, total
RNA was processed using an RNeasy Mini Kit (Qiagen, Mis-
sissauga, Ontario, Canada). Amplification reactions were pre-
pared by adding RNA (25 ng) to TaqMan One Step RT-PCR
Master Mix (4309169; Applied Biosystems Inc., Streetsville,
Ontario, Canada) containing primers to rat type II collagen
(Rn00564954_m1), aggrecan 1 (Rn00573424_m1), link pro-
tein (Rn00569884_m1), or GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase; 4308313; Applied Biosystems Inc.).
Reverse transcription and qPCR reactions were performed in
a Prism 7900 HT Sequence Detector (Applied Biosystems
Inc.). Briefly, samples were incubated for 30 min at 48°C to
make cDNA templates, followed by a maximum of 40 amplifi-
cation cycles, alternating between 95°C for 15 seconds and
60°C for 1 minute. Results were analyzed using SDS v2.1
software (Applied Biosystems Inc.).
Luciferase reporter analysis
Cells from confluent cultures were detached using trypsin-
EDTA (Invitrogen Life Technologies Inc.), pelleted, resus-
pended in serum-free culture medium, plated into 48-well
dishes (3.4 × 104 cells/well) and transfected with reporter
plasmids. The reporter plasmids included the following: a κB
reporter (BD Biosciences, Mississauga, Ontario, Canada),
comprising four tandem repeats of the κB response element
upstream of the firefly luciferase reporter sequence, expressed
upon NF-κB activation; a retinoic acid response element
(RARE) firefly luciferase reporter (pWl-β RARE3-luc), regu-
lated by activation of RARs via retinoic acid [28]; and a type II
collagen enhancer luciferase reporter containing four repeats
of the 48-bp minimal enhancer of the type II collagen gene
(pGL3 [4 × 48]) [28], each with a binding site for Sox9. Previ-
ous studies have shown that multiple repeats of the minimal
enhancer are required for optimal output [29]. For some exper-
iments, chondrocytes were co-transfected with reporter con-
structs and expression constructs for constitutively active
mitogen-activated protein kinase kinase kinase (caMEKK)1
(Clontech, Mountain View, CA, USA), a phosphorylation site-
deficient IκB (IκB-2N; pSVK3-IκB-2NΔ4) [30], or p300. In all
experiments, chondrocytes were co-transfected with a 0.002
μg renilla luciferase plasmid (pRL-SV40; Promega), which
was used in most cases to control for transfection efficiency.
Suspended chondrocytes were transfected with equal
amounts of DNA (0.052 μg of each vector and additional
pBluescript vector plasmid [Stratagene, La Jolla, CA, USA] if
necessary), using 2.25 μl Fugene 6 transfection reagent
(Roche Diagnostics Corporation, Indianapolis, IN, USA) per
microgram of DNA. After 24 hours of incubation in serum-con-
taining culture medium, chondrocytes were incubated in
serum-free medium (control medium), TNF-α (Sigma Aldrich,
Mississauga, Ontario, Canada), atRA (Sigma Aldrich), or a
combination of TNF-α and atRA for 24 hours. Luciferase activ-
ity was measured using the Dual Luciferase Assay System
(Promega) in an L-max II microplate reader (Molecular
Devices, Sunnyvale, CA, USA).
In experiments involving over-expression of p300, we noted a
mean (± standard deviation) fold increase in activity of 1.6 ±
0.2 (P < 0.03) of the SV40 constitutive promoter, which drives
the expression of renilla luciferase. Therefore, in these experi-
ments, only Sox9-driven luciferase activity was analyzed.
Antibodies
Antibodies used in these studies were anti-Sox9 (H-90), anti-
NF-κB p65 (C-20) and anti-RARα (C-20) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); anti-β-catenin (C-
2206) from Sigma Aldrich; and horseradish peroxidase-conju-
gated goat-anti-rabbit secondary antibody from Pierce Bio-
technology Inc. (Rockford, IL, USA).
Preparation of nuclear extracts, immunoblotting, and 
electrophoretic mobility shift assays
Confluent cultures were serum-deprived overnight before
addition of TNF-α and/or atRA for 24 hours. Nuclear extracts
were prepared using a method modified from that reported by
Dignam and coworkers [31], as previously described [13].
Equal concentrations (30 μg) of nuclear protein extracts were
resolved by electrophoresis on 7.5% SDS-polyacrylamide
gels. Proteins were transferred onto nitrocellulose membrane
(Protran; Schleicher & Schuell, Keene, NH, USA) by electrob-
lotting, and equivalency of loading was verified by staining with
Ponceau red. Membranes were blocked in 5% nonfat milk
(Carnation, North York, Ontario, Canada) in Tris-buffered
saline plus 0.05% Tween 20 for 1 hour, followed by incubation
with the primary antibody overnight in blocking buffer. Mem-
branes were washed with Tris-buffered saline plus 0.05%
Tween 20 and incubated with horseradish peroxidase-conju-
gated secondary antibody. Protein-antibody complexes were
visualized using SuperSignal West Pico Chemiluminescent
Substrate (Pierce Biotechnology Inc.), followed by exposure
to Hyperfilm-ECL (Amersham Biosciences, Baie D'Urfé, Que-
bec, Canada). Membranes were stripped using 1 mol/l glycine
pH 2.5 before re-probing. For NF-κB p65 and RARα immuno-
blots, relative band intensities were calculated as the ratio of
the band intensity of NF-κB p65 or RARα to that of β-catenin
that served as a loading control.
Binding of nuclear protein complexes to the κB response ele-
ment or the Col2a1 48-bp minimal enhancer sequence was
determined by electrophoretic mobility shift assays (EMSAs),
as described previously [13]. The double-stranded oligonucle-
otide containing the κB cognate sequence (5'-AGTTGAG-
GGGACTTTCCCAGG-3') was purchased from Santa Cruz
Biotechnology. The double-stranded oligonucleotideArthritis Research & Therapy    Vol 10 No 1    Rockel et al.
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containing the rat Col2a1  48-bp minimal enhancer (5'-
CTGTGAATCGGGCTCTGTATGCACTCGA-
GAAAAGCCCCATTCATGAGA-3'), described by Lefebvre
and coworkers [29], was obtained from Invitrogen Life Tech-
nology. Supershift or antibody interference assays were per-
formed by adding antibodies against NF-κB (2 μg) or RARα (2
μg) to the nuclear extract/DNA complex reaction for 1 hour
before electrophoresis on 4% polyacrylamide gels. Following
electrophoresis, gels were dried and exposed to Hyperfilm-MP
(Amersham Biosciences) at -80°C.
Densitometry and statistical analyses
Immunoblot films were analyzed by densitometry using Kodak
Digital Science software (Eastman Kodak, Rochester, NY,
USA). Data were analyzed by paired t-tests, or by analysis of
variance followed by Tukey's multiple comparisons tests. Nor-
malized data were log or arcsine transformed before analysis
(PRISM v2.0 software; GraphPad Software Inc., San Diego,
CA, USA). Unlabelled bars or bars labelled with the same
lower case letters are not significantly different from each
other (P > 0.05).
Results
Co-treatment with TNF-α and atRA further reduces 
expression of extracellular matrix protein genes
We first investigated how expression of extracellular matrix
genes responded to TNF-α and atRA. Chondrocytes were
treated for 24 hours with TNF-α and/or increasing concentra-
tions of atRA. Following treatment, transcript levels of type II
collagen, aggrecan core protein and link protein were deter-
mined by Northern blot analysis and/or qPCR (Figure 1). TNF-
α significantly reduced levels of type II collagen, aggrecan
core protein and link protein mRNA. Treatment of cells with
atRA reduced mRNA levels of all three matrix genes in a con-
centration-dependent manner. Interestingly, co-treatment of
cells with TNF-α and atRA decreased levels of these tran-
scripts more than each factor alone. These results suggest
that signalling from TNF-α and atRA converge to influence the
activity of transcription factors, such as Sox9, that are neces-
sary for the expression of cartilage matrix genes.
Effects of TNF-α and atRA on Sox9 activity
We investigated the activity of Sox9 using a reporter construct
based on the type II collagen minimal enhancer (Figure 2a).
TNF-α significantly reduced Sox9 reporter activity (approxi-
mately 47%). Sox9 reporter activity also decreased with
increasing concentrations of atRA. At 10-9 mol/l atRA, co-
treatment with TNF-α resulted in a further decrease in Sox9
reporter activity, which is consistent with the observed
changes in expression of cartilage matrix protein transcripts.
Previously, we found that regulation of Sox9 activity at the type
II collagen enhancer was dependent on NF-κB activation [13].
To determine whether the effects of TNF-α and atRA were
both mediated by NF-κB, we restricted NF-κB nuclear translo-
cation by over-expression of IκB-2N – an IκBα that is resistant
to phosphorylations required for NF-κB release (Figure 2b).
IκB-2N did not significantly alter basal Sox9 activity or the
reduction of Sox9 activity following atRA treatment alone. In
contrast, IκB-2N did eliminate the further reduction observed
in the presence of both TNF-α and atRA (10-9 mol/l). These
results indicate that reduction of Sox9 activity by atRA is inde-
pendent of NF-κB activation.
Binding of protein complexes to the Col2a1 48-bp 
minimal enhancer and nuclear Sox9 levels
Since Sox9 activity was decreased by TNF-α and atRA, we
determined whether there were changes in protein complex
binding to the Col2a1 48-bp minimal enhancer sequence or
alterations in nuclear levels of Sox9. Chondrocytes were
treated with TNF-α and nuclear extracts were analyzed by
EMSA. TNF-α did not change the amount of protein complex
bound to the 48-bp minimal enhancer sequence (Figure 3a).
In addition, TNF-α and atRA (alone or in combination) did not
change nuclear levels of Sox9 assessed by immunoblot (Fig-
ure 3b). Taken together, these findings indicate that the
observed changes in Sox9 activity are independent of
changes in DNA binding or nuclear protein levels.
atRA reduces NF-κB activity in a concentration-
dependent manner
On their own, TNF-α (30 ng/ml) and atRA (10-9 mol/l) reduced
Sox-9 activity by about 50%, and together activity was
reduced by about 75% (Figure 2a). Because their effects were
not completely additive, we determined whether there are
interactions between atRA and TNF-α signalling that influence
NF-κB or RAR activity. Chondrocytes were transfected with a
κB luciferase reporter construct and were treated with TNF-α
and/or atRA (Figure 4a). As expected, TNF-α induced NF-κB
activity. atRA alone had no effect on basal NF-κB activity.
However, atRA significantly inhibited TNF-α-activated NF-κB
activity, suggesting that active RARs suppress NF-κB activity.
We next evaluated whether activation of NF-κB influences
RAR function. Chondrocytes were transfected with a RARE
reporter and treated with TNF-α and/or atRA (Figure 4b). As
expected, atRA increased RAR activity in a concentration-
dependent manner. TNF-α did not change basal or atRA-
induced RAR activity. Thus, under these conditions, NF-κB
had no inhibitory effect on RAR activity.
atRA inhibits binding of DNA by the TNF-α-activated 
complex
To define further the inhibitory effect of atRA on NF-κB activity,
we examined the effects of atRA on nuclear localization of NF-
κB and its affinity for DNA. The presence of NF-κB p65 in
nuclear extracts from chondrocytes treated with TNF-α and/or
atRA was analyzed by immunoblot (Figure 5). TNF-α, but not
atRA, induced nuclear localization of the NF-κB p65 isoform
(Figure 5a,b). Furthermore, in the presence of TNF-α,Available online http://arthritis-research.com/content/10/1/R3
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treatment of cells with atRA did not significantly reduce the
amount of nuclear p65. Moreover, no significant changes in
nuclear levels of RARα protein were observed (Figure 5a,c).
Thus, reduction in functional activity of NF-κB was not associ-
ated with changes in nuclear levels of NF-κB p65 or RARα.
We next evaluated the possibility that RAR activation changes
the binding of NF-κB to DNA. Nuclear extracts of cells treated
with TNF-α and/or atRA were analyzed by EMSA and super-
shift/antibody interference assays (Figure 6). TNF-α, but not
atRA, induced formation of a complex bound to the κB con-
sensus site that contained the NF-κB p65 isoform. Interest-
ingly, addition of anti-RARα antibody reduced the TNF-α-
activated complex, indicating that RARα is a member of this
complex (Figure 6; compare lanes 2 and 4, and lanes 10 and
12). Furthermore, atRA decreased the intensity of TNF-α-acti-
vated complexes bound to the κB consensus site (Figure 6;
compare lanes 2 and 8 to 10). When chondrocytes were
treated with both TNF-α and atRA, the complex that remained
bound to DNA contained p65 and RARα (Figure 6; compare
lanes 10, 11 and 12). Taken together, we conclude that atRA
Figure 1
Effects of TNF-α and atRA on matrix gene expression Effects of TNF-α and atRA on matrix gene expression. Chondrocytes were treated with or without tumour necrosis factor (TNF)-α (30 ng/ml) and/or 
all-trans retinoic acid (atRA; 1, 10, or 100 nmol/l) for 24 hours. Total RNA was evaluated for aggrecan core protein (ACP), type II collagen (Col2a1) 
and 18S rRNA by (a) Northern blot analysis and by (b, c) quantitative real-time PCR, whereas link protein mRNA was evaluated only by (d) quantita-
tive real-time PCR. TNF-α and atRA alone decreased aggrecan, type II collagen and link protein transcript levels. Co-treatment with TNF-α and atRA 
further decreased mRNA transcript levels of aggrecan, type II collagen and link protein. Panel a: Northern blots are representative of three independ-
ent experiments; 18S rRNA levels were used to verify equal loading. Panels b to d: data are ratios of matrix gene: Gapdh transcript levels normalized 
as a fraction of the ratios in untreated cultures (first bar), and are expressed as means ± standard error (the number of independent experiments was 
seven for panel b, five for panel c, and five for panel d). Data were evaluated by one-way analysis of variance and Tukey's multiple comparisons test. 
Unlabelled bars or bars labelled with the same lower case letters are not significantly different (P > 0.05).Arthritis Research & Therapy    Vol 10 No 1    Rockel et al.
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binding to RARα decreases the affinity for DNA of the p65/
RARα complex that is formed in response to TNF-α.
MEKK1 inhibits the effect of atRA on NF-κB functional 
activity
Changes in transcription factor function can result from alter-
ations in the level or activity of the transcription factor itself or
of its required co-factors. Active MEKK1 induces NF-κB
nuclear localization by promoting the degradation of IκB [32].
Figure 2
Effects of TNF-α and atRA on Sox9 activity Effects of TNF-α and atRA on Sox9 activity. Chondrocytes were trans-
fected with (a) the type II collagen enhancer luciferase reporter and 
some cultures were also co-transfected with (b) a phosphorylation site-
deficient inhibitor of nuclear factor-κB (IκB-2N). Cultures were then 
treated with or without tumour necrosis factor (TNF)-α (30 ng/ml) and/
or all-trans retinoic acid (atRA; 1, 10, or 100 nmol/l) for 24 hours. Pan-
els a: TNF-α and atRA separately decreased Sox9 activity. Greater 
decreases in Sox9 activity were induced by treatment with TNF-α and 
atRA (1 nmol/l). Panel b: IκB-2N did not significantly increase basal lev-
els of Sox9 activity (1.3 ± 0.2 fold increase [mean ± standard devia-
tion]) compared with untreated cells transfected with Sox9 reporter 
only (P > 0.05). IκB-2N attenuated the effect of TNF-α on Sox9 activity, 
but regulation of Sox9 activity by atRA was maintained. Data are ratios 
of Sox9-regulated firefly luciferase units to constitutive SV40-regulated 
renilla luciferase units, normalized as a fraction of the ratios in untreated 
cultures (first bar), and are expressed as means ± standard error (the 
number of independent experiments was six for panel a and four for 
panel b). Data were evaluated by repeated measures analysis of vari-
ance and Tukey's multiple comparisons test. Unlabelled bars or bars 
labelled with the same lower case letters are not significantly different 
(P > 0.05).
Figure 3
Effect of TNF-α on Sox9-DNA binding and Sox9 nuclear protein levels Effect of TNF-α on Sox9-DNA binding and Sox9 nuclear protein levels. 
(a) Chondrocytes were treated for 24 hours with or without tumour 
necrosis factor (TNF)-α (30 ng/ml). Nuclear extracts (10 μg) were incu-
bated with double-stranded 32P-labelled oligonucleotides correspond-
ing to the Col2a1 minimal enhancer sequence and resolved on a 4% 
polyacrylamide gel. Where indicated, excess unlabelled specific oligo-
nucleotides (a: 40× or b: 80×) were added as competitors. TNF-α did 
not change the amount of protein complex (arrowhead) bound to the 
oligonucleotide. Results shown are representative of three independent 
experiments. (b) Chondrocytes were treated for 24 hours with or with-
out TNF-α (30 ng/ml) and/or atRA (100 nmol/l). Nuclear extracts (30 
μg) were resolved on a 7.5% polyacrylamide gel and immunoblotted 
with antibody recognizing Sox9. The 64 kDa band corresponding to 
Sox9 (arrowhead) was quantified by densitometry. Data were normal-
ized as a fraction of band density in untreated chondrocytes and are 
expressed as means ± standard error (three independent experiments). 
Data were evaluated by one-way analysis of variance. There was no sig-
nificant change in the level of Sox9 nuclear protein (P > 0.05).Available online http://arthritis-research.com/content/10/1/R3
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In addition, MEKK1 phosphorylates p300, increasing its his-
tone acetylase activity [33]. Thus, the effect of active MEKK1
on NF-κB and RAR activity was investigated.
Chondrocytes were co-transfected with a caMEKK1 expres-
sion construct and either κB or RARE reporter constructs (Fig-
ure 7). caMEKK1 dramatically increased basal NF-κB activity.
For example, basal NF-κB activity was enhanced approxi-
mately 24-fold in the experiment shown (compare first
columns in Figure 7a and Figure 4a from the same represent-
ative experiment; P < 0.001). Treatment of caMEKK1-trans-
fected chondrocytes with TNF-α did not further increase NF-
κB activity; however, activity levels were still 4-fold greater
than those in cells transfected with reporter alone and treated
with TNF-α (compare second columns in Figure 7a and Figure
Figure 4
Effect of atRA on NF-κB and RAR activity Effect of atRA on NF-κB and RAR activity. Chondrocytes were trans-
fected with (a) a κB reporter or (b) a retinoic acid response element 
(RARE) reporter and treated with or without tumour necrosis factor 
(TNF)-α (30 ng/ml) and/or all-trans retinoic acid (atRA; 1, 10, or 100 
nmol/l) for 24 hours. Panel a: TNF-α-induced nuclear factor-κB (NF-κB) 
activity was reduced by atRA in a concentration-dependent manner. 
Panel b: TNF-α had no effect on the concentration-dependent 
increases in RAR activity. Data are ratios of NF-κB- or retinoic acid 
receptor (RAR)-regulated firefly luciferase units to constitutive SV40-
regulated renilla luciferase units, and are means ± standard error 
(based on at least three replicates) from a single experiment, represent-
ative of three independent experiments. Data were evaluated by one-
way analysis of variance and Tukey's multiple comparisons tests. Unla-
belled bars or bars labelled with the same lower case letters are not 
significantly different (P > 0.05). RLU, relative luciferase units.
Figure 5
Effects of TNF-α and atRA on nuclear levels of NF-κB and RARα Effects of TNF-α and atRA on nuclear levels of NF-κB and RARα. 
Chondrocytes were treated with or without tumour necrosis factor 
(TNF)-α (30 ng/ml) and/or all-trans retinoic acid (atRA; 1, 10, or 100 
nmol/l) for 24 hours. (a) Nuclear extracts (30 μg) were resolved on a 
7.5% polyacrylamide gel and immunoblotted with antibodies against 
nuclear factor-κB (NF-κB) p65, retinoic acid receptor (RAR)α, or β-cat-
enin (β-cat). Signal intensities for (b) NF-κB p65 and (c) RARα were 
quantified by densitometry. Panels (a) and (b): TNF-α induced nuclear 
localization of NF-κB, which was not significantly reduced by atRA. 
Panels (a) and (c): RARα nuclear levels were not significantly altered 
by treatment with TNF-α or atRA. Panel a: The immunoblots shown are 
representative of three independent experiments. Panels (b) and (c): 
data are expressed as ratios of intensities of NF-κB or RARα to β-cat-
enin and are means ± standard error. Data were evaluated by one-way 
analysis of variance and Tukey's multiple comparisons tests. Unlabelled 
bars or bars labelled with the same lower case letters are not signifi-
cantly different (P > 0.05).Arthritis Research & Therapy    Vol 10 No 1    Rockel et al.
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4a). Interestingly, treatment of caMEKK1-transfected chondro-
cytes with atRA, alone or in combination with TNF-α, did not
reduce NF-κB activity (Figure 7a). Thus, NF-κB function was
maximized by caMEKK1 and was also protected from inhibi-
tion by atRA.
RAR activity was not altered by expression of caMEKK1 in
either the absence or presence of TNF-α (compare first two
columns in Figure 7b and Figure 4b). In contrast, atRA-
induced RAR activity was increased approximately 11-fold in
caMEKK1-transfected chondrocytes compared with cells
transfected with reporter alone (compare Figure 7b and Figure
4b; P < 0.001). To determine the effect of NF-κB activation by
caMEKK1 on RAR function, cells were co-transfected with
caMEKK1 and IκB-2N. IκB-2N inhibits NF-κB activation but
should not affect other signalling events initiated by caMEKK1.
Figure 6
Effect of atRA on NF-κB/DNA binding Effect of atRA on NF-κB/DNA binding. Chondrocytes were treated with 
or without tumour necrosis factor (TNF)-α (30 ng/ml) and/or all-trans 
retinoic acid (atRA; 1, 10, or 100 nmol/l) for 24 hours. Nuclear extracts 
were incubated with 32P-radiolabelled κB consensus DNA and 
resolved on a 4% polyacrylamide gel. TNF-α induced the formation of a 
complex of proteins that contained both nuclear factor-κB (NF-κB) p65 
and retinoic acid receptor (RAR)α bound to the κB consensus site (a, 
lane 2). Addition of antibody against NF-κB p65 gave rise to a super-
shifted complex (b, lanes 3 and 11). Antibody against RARα interfered 
with binding of the complex to DNA (lanes 4 and 12). atRA decreased 
the amount of TNF-α-activated complex bound to the κB consensus 
site in a concentration-dependent manner (lanes 8 to 10). The TNF-α-
activated complex that remained bound in the presence of atRA (0.1 
μmol/l) contained p65 and RARα (lanes 11 and 12). Results shown are 
representative of three independent experiments.
Figure 7
Effect of caMEKK1 on NF-κB and RAR activities Effect of caMEKK1 on NF-κB and RAR activities. Chondrocytes were 
co-transfected with a constitutively active mitogen-activated protein 
kinase kinase kinase (caMEKK)1 expression vector and (a) nuclear fac-
tor-κB (NF-κB) or (b) retinoic acid response element (RARE) reporter 
vectors. Cells were then treated with or without tumour necrosis factor 
(TNF)-α (30 ng/ml) and/or all-trans retinoic acid (atRA; 100 nmol/l) for 
24 hours. Panel a: caMEKK1 increased basal NF-κB activity and this 
level was not further increased by TNF-α. atRA had no effect on the 
level of caMEKK1-induced NF-κB activity. Panel b: atRA significantly 
increased RAR activity. Co-transfection with the IκB-2N expression 
vector inhibited NF-κB activity and further increased atRA-induced 
RAR activity (b, P < 0.001). Data are ratios of NF-κB- or RAR-regulated 
firefly luciferase units to constitutive SV40-regulated renilla luciferase 
units, and are means ± standard error (n = 3) from a single experiment, 
representative of three independent experiments. Data were evaluated 
by one-way analysis of variance and Tukey's multiple comparisons 
tests. Unlabelled bars or bars labelled with the same lower case letters 
are not significantly different (P > 0.05).Available online http://arthritis-research.com/content/10/1/R3
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As expected, IκB-2N inhibited NF-κB activity induced by
caMEKK1 (Figure 7a). Surprisingly, IκB-2N dramatically
increased atRA-induced RAR activity in MEKK1-transfected
cells (Figure 7b).
In summary, caMEKK1 increases the functional activity of both
NF-κB and atRA-induced RARs. Furthermore, in caMEKK1
expressing cells, atRA does not reduce NF-κB function.
Finally, inhibition of NF-κB further enhances the effect of
caMEKK1 on atRA-induced RAR function. It is likely that the
caMEKK1-induced increases in NF-κB and RAR activity are
mediated by hyperactivation of p300.
caMEKK1 attenuates TNF-α and atRA-induced decrease 
in Sox9 activity
To investigate the effect of caMEKK1 expression on Sox9
functional activity, cells were co-transfected with the
caMEKK1 expression construct and the Sox9 reporter. Over-
expression of caMEKK1 significantly increased basal Sox9
activity compared with cells lacking caMEKK1. A comparison
of the non-normalized data from the first columns of Figure 8a
and Figure 2a revealed that caMEKK1 increased Sox9 activity
by 3.7 ± 0.7 fold (mean ± standard deviation; P < 0.01; data
are from the same series of experiments). Moreover, in con-
trast to the reductions in Sox9 activity observed in cells lacking
caMEKK1 (Figure 2a), TNF-α significantly increased Sox9
activity (Figure 8a). atRA significantly reduced Sox9 activity in
cells expressing caMEKK1, but only at the highest concentra-
tion used (Figure 8a). In summary, caMEKK1 increased Sox9
functional activity, as it did NF-κB and RAR functional activity.
caMEKK1 also reversed the inhibitory effect of TNF-α on Sox9
activity. Finally, the sensitivity of Sox9 to atRA was reduced by
caMEKK1 expression. Thus, the activity state of p300, the
common co-factor and MEKK1 target, probably plays a vital
role in regulating Sox9, NF-κB and RAR function.
Sox9 functional activity is dependent on availability of 
p300
We next investigated directly whether availability of p300 con-
tributes to the reduction in Sox9 activity induced by activation
of NF-κB and RARs. Cells were co-transfected with the Sox9
reporter and a p300 expression construct. Cells over-express-
ing p300 exhibited significantly increased Sox9 activity com-
pared with cells transfected with Sox9 reporter alone (Figure
8b). Ectopic p300 expression did not prevent reductions in
Sox9 activity in response to TNF-α and atRA. However, under
most conditions, over-expression of p300 maintained Sox9
activity at a level comparable to that observed in normal,
untreated chondrocytes. Thus, increasing the availability of
p300 increases Sox9 activity even when NF-κB and RARs are
active.
Figure 8
Effect of caMEKK1 and ectopic p300 on Sox9 activity Effect of caMEKK1 and ectopic p300 on Sox9 activity. (a) Chondro-
cytes were co-transfected with the Sox9 reporter and constitutively 
active mitogen-activated protein kinase kinase kinase (caMEKK)1 
expression vector and treated for 24 hours with or without tumour 
necrosis factor (TNF)-α (30 ng/ml) and/or all-trans retinoic acid (atRA; 
1, 10, or 100 nmol/l). TNF-α significantly increased Sox9 activity, 
whereas the highest concentration of atRA decreased Sox9 activity. 
Co-treatment with atRA and TNF-α resulted in Sox9 activity levels 
equivalent to that observed in untreated cultures containing caMEKK1 
(first bar). Data are ratios of Sox9-regulated firefly luciferase units to 
renilla luciferase units normalized as a fraction of the ratio in untreated 
cultures (first bar), and are expressed as means ± standard error. Data 
were evaluated by repeated measures analysis of variance and Tukey's 
multiple comparisons test (three independent experiments). Bars 
labelled with the same lower case letters are not significantly different 
(P > 0.05). (b) Chondrocytes were transfected with Sox9 reporter 
alone (closed bars) or in combination with p300 expression vector 
(open bars) and then treated with TNF-α and/or atRA, as indicated. Co-
transfection with the p300 expression vector significantly increased 
Sox9 activity in comparison with similarly treated normal cells (* signifi-
cant effect of p300, P < 0.05). Under most conditions, over-expression 
of p300 also maintained Sox9 activity at a level comparable to that 
observed in normal, untreated chondrocytes (first closed bar). Data are 
Sox9-regulated luciferase units normalized to level in normal, untreated 
chondrocytes. #Significant difference compared with the first closed 
bar (P < 0.05). Data are means ± standard error (three independent 
experiments). Data were analyzed by paired t-tests.Arthritis Research & Therapy    Vol 10 No 1    Rockel et al.
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Discussion
Regulation of Sox9 activity through activation of NF-κB 
and RARs
Sox9 is required for expression of cartilage matrix genes [4-6].
We demonstrated a reduction in Sox9 activity after treatment
with atRA or TNF-α, consistent with previous reports of the
individual effects of these factors in condensing mesenchymal
cells and articular chondrocytes [13,28]. We extended these
studies by treating chondrocytes with both atRA and TNF-α,
revealing a further decrease in Sox9 activity compared with
each factor alone. Such a loss could be attributable to either a
reduction in Sox9 protein level or altered activity. However, we
found no effect of TNF-α or atRA on Sox9 nuclear protein lev-
els. Moreover, TNF-α did not alter the level of protein com-
plexes bound to the Col2a1  48-bp minimal enhancer
sequence. Consistent with these findings, previous studies
have shown that levels and stability of Sox9 mRNA are not
altered over a 24-hour period following treatment of mouse
chondrocytes with 0.1 μmol/l atRA [34], which is the highest
concentration used in the present study. In other studies, TNF-
α partially reduces Sox9 protein levels over a period of 8 hours
through a NF-κB-dependent, post-transcriptional mechanism
in mouse chondrocytes [15,35]. In our system, changes in
activity of Sox9 in response to TNF-α and atRA are probably
due to alternate modes of regulation, independent of changes
in protein levels or DNA binding.
For full gene transactivation function, Sox9 requires the
recruitment of the histone acetylase p300 [25,36]. p300 is a
common co-factor that is required by multiple transcription
factors, including Sox9, NF-κB and RARs, for full activity. In
the present study, ectopic expression of p300 increased basal
Sox9 activity. Moreover, increasing p300 levels maintained
Sox9 activity in the presence of TNF-α and atRA, at a level
comparable to that observed in normal, untreated cells. The
over-expression of p300 did not attenuate the reductions in
Sox9 activity induced by NF-κB and RAR activation, suggest-
ing that greater expression of p300 is necessary to overcome
these reductions. In contrast, caMEKK1, which hyperactivates
p300, attenuated the reductions in Sox9 activity; this suggests
that both p300 levels and activity are limiting in chondrocytes.
Further evidence that p300 is a limiting co-factor in chondro-
cytes comes from studies of genetically modified mice.
Animals heterozygous for p300 or its closely related family
member Cbp exhibit growth abnormalities, including defects
in bone and cartilage [37,38]. Consequently, activation of
transcription factors that sequester p300 (such as NF-κB and
RARs) may suppress cartilage matrix synthesis.
Reductions in p300 availability or activity may contribute to the
teratogenic effects of retinoids. Imbalances in atRA have major
effects on chondrocyte development. atRA inhibits the expres-
sion of Sox9 in chondroprogenitor cells, resulting in major car-
tilage and bone abnormalities [39]. In addition, acute arthritic
symptoms can arise when patients are treated with retinoids
for dermatologic disorders such as acne [40,41], which is
consistent with the effects of retinoids in mice [19] and is pos-
sibly due to reduced cartilage matrix production [18].
Interactions between NF-κB and RARs
In the present study we observed decreases in the functional
activity of NF-κB in the presence of atRA, which is consistent
with the decreases in NF-κB/DNA interactions seen in macro-
phages treated with the atRA analogue TTNPB. In addition,
over-expression of p300 rescues NF-κB activity reduced by 9-
cis RA activation of retinoid X receptors [22]. Our results sug-
gest that atRA-activated RARs not only limit p300 availability
for Sox9 but also limit its availability for activated NF-κB. On
the other hand, NF-κB activation can influence retinoid
responsive elements. For example, over-expression of NF-κB
p50 or p65 decreases 9-cis RA-activated retinoid X receptor
activity in macrophages [22]. However, we found no recipro-
cal reduction in RAR activity when chondrocytes were treated
with both TNF-α and atRA.
Regulation of transcription factor activity by p300
Differences in the affinity for p300 may contribute to the pat-
tern of regulation of transcription factor activity observed in the
present study. Because atRA reduced both Sox9 and NF-κB
activity in chondrocytes, active RARs may have a higher affinity
for p300 compared with Sox9 or NF-κB. Thus, active RARs
would be able to transactivate genes optimally, even when NF-
κB has translocated to the nucleus. NF-κB and Sox9 appear
to have similar command of p300, because Sox9 activity was
reduced by approximately 50% when NF-κB was activated.
However, the demand for p300 is controlled not only by rela-
tive affinity but also by relative stoichiometry of the transcrip-
tion factors activated in the nucleus.
Manipulating the acetylase activity of p300 can reveal its role
in regulating the function of transcription factors. In the
present study, caMEKK1 enhanced the functional activities of
NF-κB, RARs and Sox9. One explanation for these increases
is post-translational modification of p300. p300 is phosphor-
ylated in both the carboxyl-terminal and amino-terminal regions
by a kinase in the MEKK1 pathway, resulting in increased
acetylase activity [33]. In the present study, caMEKK1
increased NF-κB, atRA-induced RAR and Sox9 activity,
suggesting that hyperactive p300 can circumvent its own lim-
iting levels.
Another explanation for increased transcription factor activity
in response to active MEKK1 is increased nuclear transloca-
tion of specific transcription factors. Active MEKK1 initiates
the degradation of IκB, freeing NF-κB to enter the nucleus
[32,42]. Therefore, the maximization of NF-κB activity induced
by caMEKK1 observed in the present study may result from
activating more NF-κB than is possible with TNF-α alone.
Under basal conditions, NF-κB activation did not reduce RARAvailable online http://arthritis-research.com/content/10/1/R3
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activity; however, when NF-κB was maximally activated by
caMEKK1, it did suppress RAR activity. This effect is likely due
to increased nuclear NF-κB sequestering a greater proportion
of p300.
The additional increases to Sox9 activity induced by caMEKK1
and TNF-α observed in the present study suggest other post-
translational modifications to Sox9 or p300 by signals initiated
by TNF-α that are independent of hyperactivated p300. The
possible mechanisms associated with this regulation require
further investigation.
Increases in transcription factor activity can also result from
direct acetylation by p300, as seen with NF-κB [43]. Human
NF-κB p65 has three lysine (K) residues that are targets of
acetylation by p300, each serving a different role. Acetylation
of K221 is required for DNA binding and, in conjunction with
acetylation of K218, inhibits association with IκBα. Reduced
p300 availability or activity would decrease acetylation at the
K221 site, thereby suppressing NF-κB binding to DNA. This
mechanism could contribute to the reduction in binding to
DNA of the TNF-α-activated complex observed under condi-
tions in which chondrocytes were subjected to both TNF-α
and atRA. Acetylation at K218 is probably unaffected,
because we did not observe any changes in nuclear localiza-
tion of NF-κB p65 in the presence of both TNF-α and atRA.
More interestingly, acetylation of K310 is required for full NF-
κB transcriptional activity. Hyperactivation of p300 induced by
caMEKK1 could cause changes in NF-κB acetylation, leading
to maximal NF-κB functional activity. In particular, increased
acetylation of K310 may explain part of the increase in NF-κB
activity that we observed when caMEKK1 is expressed in the
chondrocytes. Thus, active MEKK1 may increase the acety-
lase function of p300, allowing associated transcription fac-
tors (such as those studied here) to overcome the limiting
levels of p300 and increase their activity.
Conclusion
In this study, we investigated how active transcription factors,
sharing common co-factors, regulate gene expression. We
have shown that Sox9 activity and expression of cartilage
matrix genes are limited by coincident activation of NF-κB and
RARs. We have also shown that Sox9 activity can be main-
tained in the presence of TNF-α or atRA by ectopically over-
expressing p300 or increasing p300 acetylase function. Thus,
crosstalk among Sox9, NF-κB and RARs involving p300 rep-
resents a key mechanism for the coordinated regulation of
matrix gene expression in chondrocytes. Moreover, p300 may
be a relevant target for therapeutic intervention in arthritis.
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